AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Raymond James initiates coverage on Biohaven with Strong Buy rating, PT $75
ByAinvest
Wednesday, Sep 3, 2025 12:46 pm ET1min read
Raymond James initiates coverage on Biohaven with Strong Buy rating, PT $75
Raymond James has initiated coverage on Biohaven Pharmaceutical Holding Company Ltd. (BHVN) with a Strong Buy rating and a price target of $75. The firm's research highlights the company's robust pipeline of therapies for neurological and neuropsychiatric diseases, including rare disorders, and its recent regulatory progress.Biohaven, a United States-based commercial-stage biopharmaceutical company, focuses on improving the lives of patients with debilitating conditions. Its Neuroinnovation portfolio includes NURTEC ODT (rimegepant) for migraine treatment and a pipeline of product candidates across five platforms: CGRP receptor antagonism, glutamate modulation, MPO inhibition, Kv7 Ion Channel Activators, and Myostatin [1].
The Strong Buy rating is driven by Raymond James' optimistic outlook on Biohaven's regulatory progress and market potential, particularly for Troriluzole, a drug candidate for Spinocerebellar Ataxia (SCA). The company's AdCom (Advisory Committee) expectation aligns with the majority of applications requesting a first drug approval for a rare disease indication, which typically receive an AdCom [2].
Analysts have shown strong consensus on Biohaven's potential, with 13 analysts giving a Strong Buy rating in the past three months. The average 12-month price target is $42.50, representing a 176.15% upside from the current price of $15.39. The highest price target is $60.00, while the lowest is $19.00 [2].
Raymond James' Strong Buy rating and $75 price target reflect the firm's belief in Biohaven's strategic shifts and upcoming milestones, which justify a bullish outlook despite recent setbacks. The company's pipeline and market potential position it well for growth in the biopharmaceutical sector.
References:
[1] https://www.marketscreener.com/news/raymond-james-initiates-biohaven-at-strong-buy-with-75-price-target-ce7d59dad08ff020
[2] https://www.tipranks.com/stocks/bhvn/forecast
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet